Launch of Sales of COVID-19 Antigen Rapid Diagnostic Kits
First written in FY2021-Q2. 4 of 14 entries say "Advanced", first in FY2021-Q3. Latest entry: 2026-11-09.
Denka moved to the "Worse" side of this theme in 2026.
0 other companies' latest entry also says "Worsened".
- 2026-11-09WorsenedFinancial results presentation
「抗原迅速診断キット：前期出荷の市中在庫の調整が長期化し、出荷数量が大幅減」
抗原迅速診断キットについて、前期出荷分の市中在庫調整が長期化し、出荷数量の大幅減が通期予想の下方修正要因として示された。 - FY2026-H1Lower sales volume due to a decline in infectionsAnnual report
「Sales volume of POCT test reagents fell below the previous year because the number of COVID-19 infections declined year on year.」
Sales volume of POCT test reagents, including rapid COVID-19 antigen diagnostic kits, fell below the previous year due to a decline in infections. - FY2024-Q3RestatedAnnual report
「POCT test reagents generated higher revenue: sales of rapid COVID-19 antigen diagnostic kits fell below the previous year, but sales of combined COVID-19 and influenza virus diagnostic kits increased amid the influenza outbreak.」
The disclosure reconfirms the pattern of lower sales of rapid COVID-19 antigen diagnostic kits but higher sales of combined diagnostic kits amid the influenza outbreak, resulting in higher revenue. - FY2024-Q2Lower antigen kit sales and higher combined diagnostic kit salesAnnual report
「POCT test reagents generated higher revenue: sales of rapid COVID-19 antigen diagnostic kits fell below the previous year, but sales of combined COVID-19 and influenza virus diagnostic kits increased amid the influenza outbreak.」
Sales of rapid COVID-19 antigen diagnostic kits fell below the previous year, while sales of combined diagnostic kits increased amid the influenza outbreak, resulting in higher revenue from POCT test reagents. - FY2024-Q1Lower sales of antigen diagnostic kits due to a decline in infectionsAnnual report
「POCT test reagents generated higher revenue: sales of rapid COVID-19 antigen diagnostic kits fell below the previous year due to a decline in infections, but sales of combined COVID-19 and influenza virus diagnostic kits increased as the influenza outbreak persisted for longer.」
Sales of rapid COVID-19 antigen diagnostic kits fell below the previous year due to a decline in infections, while sales of combined diagnostic kits increased as the influenza outbreak persisted for longer. - FY2023RestatedAnnual report
「Shipments of rapid COVID-19 antigen diagnostic kits and combined COVID-19 and influenza virus diagnostic kits increased as demand for hospital testing grew with the spread of infections, but prices fell substantially due to lower reimbursement points, resulting in lower revenue.」
The disclosure reconfirms that diagnostic kit shipments increased while lower prices resulting from reduced reimbursement points led to lower revenue. - FY2023-Q2Demand expansion alongside price declinesAnnual report
「The supply volume of the rapid COVID-19 antigen diagnostic kit QuickNavi™ -COVID19 Ag increased as demand broadened through distribution to elderly care facilities via local governments and screening tests at home and in the workplace, but prices fell substantially due to lower reimbursement points, resulting in lower revenue.」
Demand and supply volume for the rapid antigen diagnostic kit expanded through distribution to elderly care facilities via local governments and testing for home and workplace use, but lower prices resulting from reduced reimbursement points led to lower revenue. - FY2023-Q1AdvancedAnnual report
「Sales of the rapid COVID-19 antigen diagnostic kit QuickNavi™ -COVID19 Ag exceeded the previous year as demand broadened through supplies to elderly care facilities and educational institutions via local governments, as well as for at-home screening tests, although prices declined due to lower reimbursement points.」
Demand for the rapid antigen diagnostic kit broadened through supplies to elderly care facilities and educational institutions via local governments and testing for home use, driving sales above the previous year. Meanwhile, prices declined due to lower reimbursement points. - FY2022-Q3RestatedAnnual report
「Sales volume of the rapid COVID-19 antigen diagnostic kit QuickNavi™ -COVID19 Ag increased, partly because it was supplied for the Ministry of Health, Labour and Welfare’s distribution program, which aims to expand the availability of rapid antigen testing as part of measures against infectious diseases.」
The disclosure continues to explain that sales volume of the rapid antigen diagnostic kit increased, partly due to supplies to the Ministry of Health, Labour and Welfare’s distribution program. - FY2022-Q2AdvancedAnnual report
「Sales volume of the rapid COVID-19 antigen diagnostic kit QuickNavi™ -COVID19 Ag increased, partly because it was supplied for the Ministry of Health, Labour and Welfare’s distribution program, which aims to expand the availability of rapid antigen testing as part of measures against infectious diseases.」
Sales volume of the rapid antigen diagnostic kit increased, partly due to supplies to the Ministry of Health, Labour and Welfare’s distribution program. - FY2022-Q1RestatedAnnual report
「Sales of the rapid COVID-19 antigen diagnostic kit QuickNavi™ -COVID19 Ag progressed steadily.」
The disclosure reconfirms that sales of the rapid COVID-19 antigen diagnostic kit launched in August 2020 have been strong. - FY2021AdvancedAnnual report
「Revenue in the Life Innovation segment was ¥42,947 million, up ¥7,436 million year on year, or 20.9%, while operating profit was ¥14,836 million, up ¥7,872 million, or 113.0%.」
Following the launch of sales of rapid COVID-19 antigen diagnostic kits, revenue in the Life Innovation segment increased 20.9% and operating profit increased 113.0%. - FY2021-Q3AdvancedAnnual report
「QuickNavi™-COVID19 Ag, a rapid COVID-19 antigen diagnostic kit launched in August last year, was produced and sold steadily.」
The disclosure states that production and sales of the rapid antigen diagnostic kit launched in August 2020 have progressed steadily. - FY2021-Q2First statedAnnual report
「In August, we began selling the rapid antigen test kit for the novel coronavirus, “QuickNavi™ -COVID19 Ag.”」
Sales of rapid COVID-19 antigen diagnostic kits began in August 2020.